ABT-737

Catalog No.S1002

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Cited by 94 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )
Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )
Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )
Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )
Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )
Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )
PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )
Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

17 Customer Reviews

Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.
Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.
Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

(B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.
Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n 3. *, p 0.05; **, p 0.01.

J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.
Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.
Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.
Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.
The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.
MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NIXpbHFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MW[yOVAhdk4EoB?=	M2TzZVczKGh?	MXnEUXNQ	MUPjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigRmNNPiC\|aWLORS=>	NX7NWHF1OjZ4NUeyPFg>
KG1a	M1j5SGNmdGxiVnnhZoltcXS7IFHzd4F6	MojLNE0yOCEQvF2=	M2LWblI1KGh?	NWjifI4zTE2VTx?=	NWXsRpFvUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Mn;mNlY2PTJ5MUK=
Kasumi-1	MnfsR4VtdCCYaXHibYxqfHliQYPzZZk>	MkfDNE0yOCEQvF2=	NFHpeVQzPCCq	M4HIb2ROW09?	MVHJR\|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NGjYWG8zPjV3MkexNi=>
KG1a	MULBdI9xfG:\|aYOgRZN{[Xl?	NGTi[GYxNTFyIN88US=>	NWHw[nZTOjRiaB?=	MkLFSG1UVw>?	MWrpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MXWyOlU2OjdzMh?=
Kasumi-1	M2jrZ2Fxd3C2b4Ppd{BCe3OjeR?=	MofWNE0yOCEQvF2=	MorzNlQhcA>?	NWG1cGpQTE2VTx?=	NXLjUVBYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M4fVRlI3PTV{N{Gy
MC-3	MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TiXlUwOTBxMkCg{txO	MWqyOEBp	NFvYUFlFVVOR	M1qy[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3;sb\|I3PDR5NkG1
HN22	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\TclIvPS95LkWvNlIvPSEQvF2=	NGP3VJYzPCCq	MUTEUXNQ	MoTMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MkjqNlY1PDd4MUW=
MC-3	MlP6RZBweHSxc3nzJGF{e2G7	NYDEb3dzPS9zMD:yNEDPxE1?	NGGxSJIzPCCq	NW\sSoJqTE2VTx?=	NFTBT5JqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	M2exfVI3PDR5NkG1
HN22	MWPBdI9xfG:\|aYOgRZN{[Xl?	MViyMlUwPy53L{KyMlUh\|ryP	M1nPSFI1KGh?	M2TvcmROW09?	MUTpcoR2[2W\|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m\|	NIHqUYkzPjR2N{[xOS=>
MOLT-4	NFm0TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[2b\|ExNTVyMECgcm0>	NFT6XGE4OiCq	MXvEUXNQ	MlfmTWM2OD1yLkG5PEDPxE1?	M4HmRVI3Ozl{M{Oy
RS4;11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxNE02ODByIH7N	MkToO\|IhcA>?	NFjRfGJFVVOR	NGPXcWxKSzVyPUCuNFAzKM7:TR?=	NUToO3lJOjZ\|OUKzN\|I>
JURKAT	NV[4O252T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTaeVgyOC13MECwJI5O	MV23NkBp	MWrEUXNQ	NI\WOppKSzVyPU[2JO69VQ>?	MlXoNlY{QTJ\|M{K=
CEM R	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HRT\|ExNTVyMECgcm0>	MVm3NkBp	Ml7LSG1UVw>?	NXztOXlUUUN3ME21MlQh\|ryP	M1v0eVI3Ozl{M{Oy
CEM S	M{HaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSxNE02ODByIH7N	Mnr1O\|IhcA>?	Ml;USG1UVw>?	MX3JR\|UxRTF{LkGg{txO	NXTrbXh{OjZ\|OUKzN\|I>
MOLT-4	M3zWXGFxd3C2b4Ppd{BCe3OjeR?=	NGHCcHAyOC1zMECwJI5O	NUHIOVF4OjRiaB?=	NVvnNplGTE2VTx?=	M1nVRoNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	MVmyOlM6OjN\|Mh?=
CEM S	NWLSVFVQSXCxcITvd4l{KEG\|c3H5	MYGxNE0yODByIH7N	NYWyfIY3OjRiaB?=	NHX2bWpFVVOR	MUDjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?=	MkPaNlY{QTJ\|M{K=
JURKAT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zEfVExOC1zMECwJI5O	MkPKOFghcA>?	M3nKVGROW09?	MkThTWM2OD17NUZCtVkvOyCwTR?=	NXLYdJFEOjZzN{KyOlk>
LOUCY	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEftbXIyODBvMUCwNEBvVQ>?	MWK0PEBp	M1XM[2ROW09?	NU\RW5dbUUN3ME2zNk45yrFzMD65JI5O	Mln5NlYyPzJ{Nkm=
WM-115	MoD3R4VtdCCYaXHibYxqfHliQYPzZZk>	M4i4O\|ExOMLibl2=	NHe2[VI4OiCq		MUjlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>?	M1K0SlI3OTF4N{e2
B16	Moi5R4VtdCCYaXHibYxqfHliQYPzZZk>	MlnrNVAxyqCwTR?=	M3P6V\|czKGh?		NV\q[JVG\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC=	NGfFfXIzPjFzNke3Oi=>
HL-60	M4DFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF[1b2s4OiCq		MYrJR\|UxyqB;IEGwMlchdk1?	M3TkV\|I3ODR3NkC5
MOLM-13	M{fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4fjWVczKGh?		NE\OOI9KSzVywrC9JFI4Njlibl2=	NVu1T5FVOjZyNEW2NFk>
OCI-AML3	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYG3NkBp		M{mwXmlEPTEEoE2gNVk2OCCwTR?=	M{TUXFI3ODR3NkC5
BCWM.1	MV\BdI9xfG:\|aYOgRZN{[Xl?	MX:wMVEvPiEQvF2=	MmXBNlQhcA>?		MX3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NHrJRoIzPTh7M{K5NC=>
MWCL-1	NVGyR\|FwSXCxcITvd4l{KEG\|c3H5	MXuwMVEvPiEQvF2=	M1e0TFI1KGh?		NYPKZ3lRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MX2yOVg6OzJ7MB?=
MM.1s	M4TX[2Fxd3C2b4Ppd{BCe3OjeR?=	NU\qbYRIOC1zLk[g{txO	MlHWNlQhcA>?		MmPTbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MUGyOVg6OzJ7MB?=
HCT116	NVnlVYVNTnWwY4Tpc44hSXO\|YYm=	M1q5[\|MwOTBizszN	MXGxNuKhcMLi	MV\EUXNQ	NE[5ZmNqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN\|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36=	MmrLNlU4OTVyMki=
HCT116 BAX BAK1 DKO	M1vXbmZ2dmO2aX;uJGF{e2G7	NUjNepViOy9zMDFOwG0>	M3[weVEzyqCqwrC=	MlH4SG1UVw>?	M1fC[4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?=	M4PLN\|I2PzF3MEK4
HCT116	NIXpNWVHfW6ldHnvckBCe3OjeR?=	NIXBOm4yOCEQvF2=	Mm\lNVLDqGkEoB?=	Mo[zSG1UVw>?	NIfXbm1qdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th	MlLSNlU4OTVyMki=
HCT116 BAX BAK1 DKO	M3XtNmZ2dmO2aX;uJGF{e2G7	MWWxNEDPxE1?	NHPKdGIyOsLiaNMg	MWHEUXNQ	MXPpcoNz\WG\|ZYOgS2ZRNUyFM1KgdJVv[3Sj	MnXyNlU4OTVyMki=
HCT116	MVTBeZRweGijZ4mgRZN{[Xl?	NVrqeJVCOTBizszN	NUPWPFV6OTMEoHlCpC=>	NUjybJVpTE2VTx?=	M{D4SYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	MW[yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO	NVvxbmVVSXW2b4DoZYd6KEG\|c3H5	NUjv[GtVOTBizszN	NIHzXWcyOsLiaNMg	MYLEUXNQ	NFXLNItqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>?	MUOyOVcyPTB{OB?=
U937	MnfmRZBweHSxc3nzJGF{e2G7	MlnrNE4yOjVvMjFOwG0>	NWTySmIxOjRiaB?=		MY\lcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?=	NEXUb2IzPTdzNECyOC=>
U937	MnrwRZBweHSxc3nzJGF{e2G7	NUPDT4pnOC53IN88US=>	NFm3XYIzPCCq		MW\lcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu	NEXqfYMzPTdzNECyOC=>
HL-60 AAA-Bcl-2	NXvjd2lJSXCxcITvd4l{KEG\|c3H5	NV73eGdzOC13IN88US=>	MWi0PEBp		MVLJR\|UxRTBwOEeg{txu97zOaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHjObIczPTdzMUS2NC=>
HL-60 EEE-Bcl-2	MWLBdI9xfG:\|aYOgRZN{[Xl?	MXywMVUh\|ryP	MUS0PEBp		NUD2UFZPUUN3ME21JO69de,:jDDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVeyOVcyOTR4MB?=
U87	NFPK[mRHfW6ldHnvckBCe3OjeR?=	NIXwNGw2OCEQvF2=	MX[yOEBp		NV3ZemhkemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=>	MnvKNlU3Pjd4NkO=
K562	M1vremNmdGxiVnnhZoltcXS7IFHzd4F6	MXyxMVExKM7:TR?=	NYnjZ5NMPDhiaB?=	M3HJPWROW09?	M4jzW2lEPTB;Mk[uO{DPxE1?	Mnq2NlU2QTZ3NkG=
K562/Mcl -1-IRESBim	M3rXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrjeFhpUUN3ME25MlMh\|ryP	NYfIcWlvOjV3M{W5NFA>
K562/Bcl- 2-IRESBim	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwM{Wg{txO	NFHUOoUzPTV\|NUmwNC=>
Jurkat	NEDq[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrCW3FKSzVyPUCuOlYh\|ryP	NXXjPHd2OjV3M{W5NFA>
JurkatΔBak	NXexVVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TGVWlEPTB-NUCg{txO	NHz3[pkzPTV\|NUmwNC=>
HL60/VCR	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33LXWlEPTB-MUCwJO69VQ>?	NWnHe5NOOjV3M{W5NFA>
Kasumi-1	NH7M[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nZb2lEPTB;MD6wNUDPxE1?	M2jwVlI2PTN3OUCw
Kasumi-1/ABT	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr0bYFKSzVyPUCuOVEh\|ryP	NUXkXYQ4OjV3M{W5NFA>
THP-1	NV7kTItzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwMkeg{txO	MoqzNlU2OzV7MEC=
U937	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jRbmlEPTB;NT6yPUDPxE1?	MlnCNlU2OzV7MEC=
C1498	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljZTWM2OD14LkGzJO69VQ>?	NGHXRpEzPTV\|NUmwNC=>
RPMI 8226	M3zwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX[3SGh3UUN3ME2wMlI2KM7:TR?=	MXuyOVU{PTlyMB?=
MM.1S	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwNECg{txO	NVnwZYtyOjV3M{W5NFA>
NCI-H929	NFjMVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jxWGlEPTB;MUWuNlEh\|ryP	Ml:yNlU2OzV7MEC=
U266	NWrwenJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnUfplXUUN3ME2wMlY5KM7:TR?=	M33DO\|I2PTN3OUCw
MCF-7	MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NETxOnQ2KM7:TR?=	MVe0PEBp	NHHjSVFFVVOR	M3X3TIVvcGGwY3XzJJRp\SC\|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25?	M2jFUVI2PDB7MUK0
MCF-7	M1XxcmFxd3C2b4Ppd{BCe3OjeR?=	NHnNNHc2KM7:TR?=	M2DFelQwOjRxNEigbC=>	M{HOdmROW09?	NYLROJRWcW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA>	NYLEXIgxOjV2MEmxNlQ>
MCF-7	NH:2TZJHfW6ldHnvckBCe3OjeR?=	NGnvWo02KM7:TR?=	MofFNlQhcA>?	M4\6SmROW09?	M{ntRYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	NVv1c\|lKOjV2MEmxNlQ>
MDA-MB 231	NG\jOXBHfW6ldHnvckBCe3OjeR?=	NVzjNYJyPSEQvF2=	MnTxNlQhcA>?	M2LqcWROW09?	MUflcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	M13WZ\|I2PDB7MUK0
ZR-75-1	MUjGeY5kfGmxbjDBd5NigQ>?	NFq0RnI2KM7:TR?=	NFK2PFAzPCCq	M3PoPGROW09?	Ml60[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW\|c3nvcuKh	M33ERVI2PDB7MUK0
A549	NVfRWm5RS2WubDDWbYFjcWyrdImgRZN{[Xl?	NVfGRZoxOC1{MDFOwG0>	MWi3NkBp	NWi0e2ppTE2VTx?=	NEfye2tl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NI\LSZUzPTN6OEe2Ni=>
H1299	MmHaR4VtdCCYaXHibYxqfHliQYPzZZk>	M{\aPFAuOjBizszN	MY[3NkBp	NIK5PZlFVVOR	M{HiSYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	MYSyOVM5QDd4Mh?=
HO-8910	NFX3Z2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3XoPVAuOjBizszN	NF;zbpA4OiCq	MXjEUXNQ	NVz6[pRI\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MXuyOVM5QDd4Mh?=
HT-29	M{\qXGNmdGxiVnnhZoltcXS7IFHzd4F6	M{myRVAuOjBizszN	NH6zbno4OiCq	MXrEUXNQ	MmPm[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	NVTpbFN6OjV\|OEi3OlI>
HCT-116	NV22[FVmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NFroOosxNTJyIN88US=>	M3HzZVczKGh?	NIXoe2RFVVOR	MUTk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	M1XRN\|I2Ozh6N{[y
A549	NXHse4VzSXCxcITvd4l{KEG\|c3H5	MXeyNEDPxE1?	NFPxO\|E1QCCq	NVy4OYZCTE2VTx?=	NVOyUmoycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG\|cHnybY4>	Mn6wNlU{QDh5NkK=
H1299	M3PGXmFxd3C2b4Ppd{BCe3OjeR?=	MkHONlAh\|ryP	NVTnPHlKPDhiaB?=	M3\wRWROW09?	MVHpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	MlHmNlU{QDh5NkK=
Sc-1	NF3hcW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGG5UncxNjByMEGtNUDPxE1?	MXe5OkBp		NU\UPItV\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	Mo\sNlU{PzN3MEi=
OcI-LY18	M1e4eWNmdGxiVnnhZoltcXS7IFHzd4F6	M2OyV\|AvODByMT2xJO69VQ>?	NH7VfVc6PiCq		NWTic3FF\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NFvQNoUzPTN5M{WwPC=>
RL	NG\wUHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVuwMlAxODFvMTFOwG0>	M2GyW\|k3KGh?		M2ntcYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MlW4NlU{PzN3MEi=
RKO	M2n0[2NmdGxiVnnhZoltcXS7IFHzd4F6	NGLIR4gxNTFyIN88US=>	MkjBNlTjiImqwrC=	NFXkcGdFVVOR	MXvJR\|UxRuLCiUK15qCKyrWP	M3fvSlI2OzB2M{iz
Caco-2	NHm2ZlhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MUCwMVExKM7:TR?=	MVKyOQKBkWkEoB?=	M3HJVmROW09?	NEWxe\|JKSzVyPUG5MlfjiIoEtV2=	MmH4NlU{ODR\|OEO=
DLD1	M1nMXmNmdGxiVnnhZoltcXS7IFHzd4F6	NHjHflExNTFyIN88US=>	MV:yOQKBkWkEoB?=	NXrXTmE4TE2VTx?=	MnnhTWM2OD1zOD63PQKBkcL3TR?=	Mli2NlU{ODR\|OEO=
LS411N	M4TVeGNmdGxiVnnhZoltcXS7IFHzd4F6	NEG5bHQxNTFyIN88US=>	MlHONlTjiImqwrC=	Mm\0SG1UVw>?	NYLyd3E5UUN3ME2xNU41P+LCidM1US=>	MUOyOVMxPDN6Mx?=
SW620	NFP1eZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MlH6NE0yOCEQvF2=	NX7LN2tiOjUkgJnoxsA>	NILuXXZFVVOR	MmfOTWM2OD1zMj6yOQKBkcL3TR?=	M3rhPVI2OzB2M{iz
HCT116	NYjIdpZmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHPpUYoxNTFyIN88US=>	NITVSYYzPOLCiXlCpC=>	NUTkeI92TE2VTx?=	M{TDUWlEPTB;MkCuOFnjiIoEtV2=	MYCyOVMxPDN6Mx?=
HaCaT	NVLiRXVqS2WubDDWbYFjcWyrdImgRZN{[Xl?	NEDqcIMxNjFxMT:xNEDPxE1?	M4K3VFI1KGh?	M16zSGROW09?	NXrBNI5W\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NHrLVYkzPTJzMEe5OS=>
A5-RT3	NUPqPXV2S2WubDDWbYFjcWyrdImgRZN{[Xl?	MVGwMlEwOS9zMDFOwG0>	MXWyOEBp	MlrFSG1UVw>?	M1G5ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnXRNlUzOTB5OUW=
HaCaT	NEPt[3VHfW6ldHnvckBCe3OjeR?=	MYixNQKBkc7:TR?=	MWGyOE81QCCq	NH2wXWJFVVOR	MVvpcoR2[2W\|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25?	M33yT\|I2OjFyN{m1
A5-RT3	MWfGeY5kfGmxbjDBd5NigQ>?	M17jeFEx6oDLzszN	MonNNlQwPDhiaB?=	NEjsSllFVVOR	MV7pcoR2[2W\|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25?	M1S4R\|I2OjFyN{m1
A5-RT3	NVzaO\|JlTnWwY4Tpc44hSXO\|YYm=	NVzaXXBnPSEQvF2=	M1njVlYhcA>?	MUXEUXNQ	MXPpcoR2[2W\|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy	MWqyOVIyODd7NR?=
U266	NYHuU2x7TnWwY4Tpc44hSXO\|YYm=	NFjHb5c2ODBxN{WwJI5O	Mn;SNlQwPDhiaB?=	MlfjSG1UVw>?	M{fubYRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	NWn5NXc{OjV{MEi4PFg>
RPMI8226	M2Xvc2Z2dmO2aX;uJGF{e2G7	M4XBO\|UxOC95NUCgcm0>	NILqRnYzPC92ODDo	NHv0NJZFVVOR	MXvkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2=	NFv3VWQzPTJyOEi4PC=>
MM.1S	MnLiSpVv[3Srb36gRZN{[Xl?	NXPJ[lFCPTByL{e1NEBvVQ>?	MUiyOE81QCCq	NHvMUWVFVVOR	MnvV[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	M2nLSFI2OjB6OEi4
Clone A	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4raOVAvOuLCk{[wJO69VQ>?	M1fmPFczKGh?	M3vYfGROW09?	MkXITWM2OD15LkWg{txO	NU\LVY42OjV{MEi4PFI>
CX-1	NWD4dFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPVW2MxNjMkgKO2NEDPxE1?	NWP4TVI4PzJiaB?=	MkHuSG1UVw>?	NVPLVI5CUUN3ME2xMlgh\|ryP	NVPVfFdEOjV{MEi4PFI>
LS174T	NV\5bnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInidFQxNjMkgKO2NEDPxE1?	NYjPeoF[PzJiaB?=	MmHKSG1UVw>?	M{LMWWlEPTB;MUiuN{DPxE1?	Mn:5NlUzODh6OEK=
HT29	MUPBdI9xfG:\|aYOgRZN{[Xl?	NXXSUW1sOS93L{GwJO69VQ>?	MUK0PEBp		MVjjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NE\RSmozPTF7MkG4PC=>
SW480	NGflUIFCeG:ydH;zbZMhSXO\|YYm=	NVLYelNZOS93L{GwJO69VQ>?	M4\MRVQ5KGh?		MnrlZ4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MV2yOVE6OjF6OB?=
Colo205	M1;aeGFxd3C2b4Ppd{BCe3OjeR?=	NF\LeWoyNzVxMUCg{txO	MUe0PEBp		MW\jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M4fBU\|I2OTl{MUi4
Caco2	MX\BdI9xfG:\|aYOgRZN{[Xl?	MljMNU82NzFyIN88US=>	NXnhb\|NPPDhiaB?=		MYDjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MX[yOVE6OjF6OB?=
PCI-13	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYS2NlhnPzJiaB?=	M4nlO2ROW09?	MmPDS2k2OD1zNTFCtUAyNjhizszN	M2KxXlI2OTN7M{i3
PCI-15B	M1TSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWfrVlBHPzJiaB?=	M1\1W2ROW09?	NIHnSZZIUTVyPUGxJOKyKDRwNTFOwG0>	M2LGbVI2OTN7M{i3
UM-SCC22B	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHKzSng4OiCq	NV31Z3Z1TE2VTx?=	Mo[4S2k2OD1zOTFCtUAzNjlizszN	NYnOVYZUOjVzM{mzPFc>
UM-SCC47	M2e1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmG2O\|IhcA>?	MYjEUXNQ	MYDHTVUxRTF7INMxJFEzNjNizszN	NV3G[IZbOjVzM{mzPFc>
93-VU-147T	NG[zdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVXvbVRYPzJiaB?=	MVLEUXNQ	NF\hNIlIUTVyPUSuN{DDuSB\|LkWg{txO	NFu4Z5czPTF\|OUO4Oy=>
UD-SCC2	M3rrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUjLSHYyPzJiaB?=	MkfESG1UVw>?	M2DwdmdKPTB;MkigxtEhOi57IN88US=>	M3vsb\|I2OTN7M{i3
UPCI:SCC90	NGLmbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{LpXFczKGh?	M3L2OWROW09?	M3jPVmdKPTB;Nj62JOKyKDFwNTFOwG0>	NFzHVGozPTF\|OUO4Oy=>
RPMI-8226	NUnrXG5WS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2TCU\|EzPS9{NUCvOVAxKG6P	NF7yNZA1QGkEoB?=	MmnaSG1UVw>?	MYLk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MlvENlUxODh{MEK=
OPM-2	NXvsZWlCS2WubDDWbYFjcWyrdImgRZN{[Xl?	NV;zdJFIOTJ3L{K1NE82ODBibl2=	NVSyW2lVPDiqwrC=	NFjMcWpFVVOR	MUPk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2POVlI2ODB6MkCy
RPMI-8226	M4LmOmFxd3C2b4Ppd{BCe3OjeR?=	NYHXNpJEOTJ3L{K1NE82ODBibl2=	NEjIfo41QGkEoB?=	NWnue29PTE2VTx?=	Mm\IbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlvRNlUxODh{MEK=
OPM-2	NE\6R4NCeG:ydH;zbZMhSXO\|YYm=	M{HYZ\|EzPS9{NUCvOVAxKG6P	NYK1SYhEPDiqwrC=	M2PW[WROW09?	MlXVbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MUWyOVAxQDJyMh?=
COG-LL-319	MXLGeY5kfGmxbjDBd5NigQ>?	NXns[IVJOTByIH7N	NFfYOJkyNzNxNjDo	NEnuU5BFVVOR	NFOxOJhqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen	M2TRfVI1QTVzNEey
RS4;11	M{fuS2Z2dmO2aX;uJGF{e2G7	Mn61NVAxKG6P	MXKxM\|MwPiCq	MoHaSG1UVw>?	NIjjV\|VqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen	NUO2XotWOjR7NUG0O\|I>

... Click to View More Cell Line Experimental Data

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	+ Expand Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%) Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% Propylene glycol, 5% Tween 80, 65% D5W For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 94 Publications

17 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737

Cited by 94 Publications

17 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download ABT-737 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)